Cindy Lampner, MSLIS

Data suggest that patients in remission with baricitinib 4 mg daily dose who have taken this medication for at least 1 year may be able to attempt baricitinib dose-tapering while continuing their methotrexate regimen.

The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.